Quarterly ResultMay 8, 2026, 04:08 PM
Oragenics Q1 Net Loss $2.2M; Going Concern Warning; Licenses CardioDialysis
AI Summary
Oragenics reported a net loss of $2.2 million for the first quarter of 2026, with cash and cash equivalents of $6.1 million and an accumulated deficit of $228.8 million. The company issued a going concern warning, indicating that current working capital is sufficient only through December 31, 2026, and additional financing is required. Operationally, the Phase IIa clinical trial for its lead product candidate, ONP-002, for mild traumatic brain injury is progressing in Australia. Post-quarter, Oragenics entered a non-binding Letter of Intent to license Sigyn Therapeutics' CardioDialysis™ technology for TBI and other chronic neurodegenerative diseases.
Key Highlights
- Net loss for Q1 2026 was $(2.20) million, compared to $(2.22) million in Q1 2025.
- Cash and cash equivalents totaled $6.11 million as of March 31, 2026.
- Accumulated deficit reached $(228.83) million as of March 31, 2026.
- Research and development expenses increased to $0.65 million in Q1 2026 from $0.34 million in Q1 2025.
- Net cash used in operating activities was $(2.20) million for Q1 2026.
- Company issued a going concern warning, with current capital funding operations through December 31, 2026.
- Entered a non-binding LOI to license CardioDialysis™ technology from Sigyn Therapeutics for TBI and neurodegenerative diseases.
- ONP-002 Phase IIa clinical trial for mild traumatic brain injury is progressing in Australia.